ViaDerma, Inc. Provides an Update of Current and Future Product Sales

LOS ANGELES, April 02, 2018 -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), is pleased to provide a update on current sales of the Company’s flagship product, Vitastem. 

ViaDerma launches Wound Care Services Licensing Program.  ViaDerma will work with experts including skilled foot and ankle surgeons, podiatrists, vascular and general surgeons, and infectious disease specialists, wound care nurses at clinics, hospitals and skilled nursing facilities. ViaDerma Wound Care protocol utilizes a comprehensive approach including the use of Vitastem topical antibiotic, to treat all wounds, but specialize in those that have become chronic or difficult to heal.

Vitastem is presently being sold over the internet on Amazon and on Vitastem.net. Vitastem.net sales have averaged about 500 units per month without advertising to this point. The Company is preparing for increased production to meet product demands before launching an official marketing campaign.

Sales in Canada of Elixr CBD products powered by ViaDerma’s patent pending transdermal delivery technology began with a successful initial test run of 1000 units. Demand for the product resulted in the first run completely selling out.  Subsequent product orders are currently being negotiating with ViaDerma’s Canadian representatives and should be announced soon.

Other products are in various stages of development and marketing.  The Company will release its annual report for year end 2017 on April 2, 2018.

Dr. Christopher Otiko, President of ViaDerma, stated, “Our sales efforts are taking shape as we prepare for larger production runs to meet upcoming sales demands. Some unforeseen delays prevented us from attaining our 2017 sales goals, however, we are putting those issues behind us and are looking forward to making 2018 our best year ever.”  

“According to GlobalData Healthcare, the wound care management market was valued at $33.9 billion in 2017.  We expect to generate revenues of $250,000 per quarter starting from Q2, 2018. This is a step to diversify our income streams and augment the consumer sales division, which has taken longer than we anticipated to take off.”

Dr. Otiko also said, “We are especially proud of the wonderful results patients and healthcare providers who have used Vitastem have experienced so far. We believe it is an excellent product, and we are working diligently to make Vitastem well known throughout the global medical community.”

About ViaDerma, Inc.

ViaDerma, Inc. (OTC:VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: www.viadermalicensing.com

Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:

Investor Relations

Email:  [email protected]

Phone: 310-374-6111